Monographie - Cefepime dihydrochloride

Ultimo aggiornamento :
18/04/2024

Cefepime dihydrochloride

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Aspime	Venezuela
Avipim	Turchia
Axépim	Francia
Baxypime	Messico
Cachepime	India
Cefalospim	Brasile
Cefemin	Colombia
Cefepem	Brasile
Cefepitax	Brasile
Cepim	Italia
Cepimex	Italia
Forcetex	Egitto
Maxcef	Brasile
Maxipime	Austria, Belgio, Canada, Colombia, Finlandia, Germania, Grecia, Italia, Lussemburgo, Perù, Polonia, Portogallo, Spagna, Stati Uniti d’America, Svezia, Turchia, Ungheria
Nebamix	Perù
Olpelinol	Messico
Pimcef	Perù
Pimerzen	Messico
Roxipime	Turchia
Unisef	Turchia
Vipefime	Messico

Bibliografia : Cefepime dihydrochloride

	Tipo	Pubblicazione
182	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
251	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
873	Rivista	Das Gupta V, Maswoswe J, Bailey RE. Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection. Int J Pharm Compound 1997 ; 1: 435-436.
921	Rivista	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1046	Rivista	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride in polypropylene syringes. Am J Health-Syst Pharm 1999 ; 56: 1134.
1068	Rivista	Stewart JT, Warren FW, Maddox FC. Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C. Am J Health-Syst Pharm 1999 ; 56: 457-459.
1290	Rivista	Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM. Stability of cefepime in peritoneal dialysis solution. Ann Pharmacotherapy 1999 ; 33: 906-909.
1410	Rivista	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1605	Rivista	Stewart JT, Maddox FC, Warren FW. Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C. Hosp Pharm 2000 ; 35: 1057-1064.
1625	Rivista	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1626	Rivista	Ling J, Das Gupta V. Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2001 ; 5: 151-152.
1648	Rivista	Schlesser V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM. Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags. Int J Pharm Compound 2002 ; 6: 391-394.
1673	Rivista	Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC. Stability study of cefepime in different infusion solutions. Int J Pharm 1997 ; 154: 185-190.
1712	Rivista	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Rivista	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Rivista	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Rivista	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Rivista	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1834	Rivista	Trissel LA, Xu QA. Stability of cefepime hydrochloride in autodose infusion system bags. Ann Pharmacotherapy 2003 ; 37, 6: 804-807.
1945	Rivista	Elwell RJ, Volino LR, Frye RF. Stability of cefepime in icodextrin peritoneal dialysis solution. Ann Pharmacotherapy 2004 ; 38: 2041-2044.
1982	Rivista	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042	Rivista	Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM. Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2046	Rivista	Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother 2003 ; 47: 1991-1994.
2134	Rivista	Fubara JO, Notari RE. Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions. J Pharm Sci 1998 ; 87, 12: 1572-1576.
2141	Rivista	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2192	Rivista	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231	Rivista	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Rivista	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3254	Rivista	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385	Rivista	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3416	Rivista	Csaba M, Boddu,S.H.S , Churchwell M.D. Physical compatibility of sodium citrate with alcohol and cefepime. Am J Health-Syst Pharm 2013 ; 70: 932-937
3520	Laboratorio	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3542	Rivista	Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion Am J Health-Syst Pharm 2015 ; 72:390-395
3548	Laboratorio	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3549	Laboratorio	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratorio	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratorio	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Rivista	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Rivista	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4055	Rivista	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Rivista	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	Rivista	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4326	Rivista	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.
4411	Rivista	Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. Int J Pharm Compound 2020 ;24,3:238-241.
4434	Rivista	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Rivista	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4465	Rivista	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4521	Rivista	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Rivista	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	Rivista	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458

Mentions Légales